Patrick Soon-Shiong wants to turn cancer treatment upside down. On January 12, Soon-Shiong and a consortium of industry, government, and academia announced the launch of the Cancer MoonShot 2020, an ambitious program aiming to replace a long history of blunt trial-and-error treatment with what amounts to a training regimen for the body’s own immune system. That system, Soon-Shiong argues, is perfectly adept at finding and eliminating cancer with exquisite precision—if it can recognize the mutated cells in the first place. Helping it to do so could represent a powerful new treatment for the disease, akin to a flu vaccine. ... Soon-Shiong has hit home runs before. This past July, one of his firms underwent the highest-value biotech IPO in history. A cancer drug he developed, called Abraxane, is approved to fight breast, lung, and pancreatic cancers in more than 40 countries. Soon-Shiong’s path from medical school in South Africa through residency in Canada, to UCLA professor, NASA researcher and corporate CEO has given him the bird’s-eye view necessary to take on a project this ambitious, as well as the resources to marshal the world-class computing and genome-sequencing facilities that it requires.
- Also: Science Alert - Scientists report "unprecedented" success using T-cells to treat cancer < 5min
- Also: Aeon - Death of cancer 5-15min
- Also: The Conversation - The equation that will help us decode cancer’s secrets < 5min
- Also: The New Yorker - Tough Medicine: A disturbing report from the front lines of the war on cancer. < 5min
- Repeat: Mosaic - What’s wrong with Craig Venter? 5-15min
Ferro, who declined to be interviewed for this story, began his career as an entrepreneur, launching companies in the 1980s and ’90s, including a software startup. By the time he met Fiasco, Ferro had long since transitioned from creating businesses to buying them—especially ones in financial trouble. And for an investor in distressed companies, few industries have targets as numerous and tempting as newspapers. ... The Ferro era at Tribune has quickly become one of the more baffling chapters in media history. Within eight months, Team Ferro has rejected one purchase offer, angering shareholders; promised to unveil a “content monetization engine” that would unleash newspapers’ true potential as a “rock star business”; posted a want ad for an employee to assist “news content harvesting robots”; rejected another, more lucrative purchase offer; rebranded Tribune as Tronc, or tronc, as the company insists; and split and re-rebranded tronc into troncM, for media, and troncX, for exchange. ... corporate renaming ignited extended spasms of #tronc mockery on social media. Sample tweet: “WHAT YOU GONNA DO WITH ALL THAT JONC ALL THAT JONC INSIDE YOUR TRONC.” ... yet, until recently, Ferro was on the verge of laughing all the way to the bonc, as it were. ... now the spotlight is back on Ferro and his vision for saving journalism.